Market Research Blog

[200 Pages Report] According to Future Market Insights (FMI), the demand for insulin pens is expected to rise considerably in the coming decade, enabling the market to surpass a valuation of US$ 30,407.5 Mn by the end of 2021.

Insulin pens are used by diabetes patients to avoid problems including cardiovascular diseases that may arise from this lifestyle-based ailment. To overcome problems related to conventional methods of insulin administration, insulin pens make the process easier and faster.

According to the WHO, approximately 1.2 million deaths were caused due to diabetes in 2019 globally. To reduce the number of deaths or sufferings due to diabetes, the development of innovative techniques and products for the treatment and maintenance of diabetes is essential.

Type 2 diabetes cases are common, but it can be prevented or delayed by a healthy diet, consistent physical activity, maintaining a standard body weight and avoiding the use of tobacco. Diabetes can be treated or managed with medicines and regular checking and treatment. Increasing focus on innovative medical products and research are increasingly driving a transition towards insulin pen by diabetes patients.

Leading manufacturers in the insulin pen market are strengthening their market position through collaborations with various health and research organizations. Governments in developed and developing countries are actively taking initiatives to encourage innovative medical products.

Request a sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-13518

For instance, in November 2020, Medtronic introduced CGM integrated smart insulin delivery pen to manage multiple daily dosage insulin injections. Similarly, Insulet expanded its offering of OmipodDASH into additional countries such as Sweden, Finland, Norway, and Denmark.

Key Takeaways from Insulin Pen Services Market Study

• Reusable insulin pens are expected to account for over 49% the global market share by 2031, supported by a growing base of environment and cost-conscious consumers.
• Hospital pharmacies will account for 33.8% of the market share in 2031. The soaring influx of patients for treatment and intensive care support supports growth.
• The U.S. is projected to be the fastest-growing regional market with a CAGR of 5.6% through 2021-2031 owing to the matured healthcare sector of the country.
• The U.K. and Germany are leading markets in Europe, accounting for more than 18% and 25% in 2021.
• China is the largest and fastest growing market in East Asia, exhibiting a 4.7% CAGR through 2031.
• Australia is leading the Oceania market, accounting for more than 85% of insulin pen revenues in 2021.

Who is Winning?

The global insulin pen market is set to expand due to the rising prevalence of type 1 and type 2 diabetes. Leading organizations within the market are set to focus on research and development to offer an early and precise diagnosis of the ailment, besides offering effective patient care.

Request a TOC@ https://www.futuremarketinsights.com/toc/rep-gb-13518

Some of the leading players in the insulin pen market include but are not limited to NovoNordisk A/S, Sanofi, Eli Lilly, Diamesco Co., Ltd., BigFoot Biomedical, Inc, Medtronic plc, Emperra GmbH E-Health Technologies, YpsoMed AG, and DUKADA Aps.

Insulin Pens Market by Category

By Product Type:

• Reusable Insulin Pen
• Refillable Pens
• Bluetooth Connected Smart Insulin Pen
• USB Connected Smart Insulin Pen
• Cartridge
• Disposable Insulin Pens
• Smart Insulin Pens Caps
• Insulin Pump

By Indication:

• Type 1
• Type 2

Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Sales
• Diabetes Clinic/Center

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

The Insulin Pumps Market revenues were estimated at US$ 5.5 Bn in 2022 and is anticipated to grow at a CAGR of 10.3% from 2022-2032, according to a recently published Future Market Insights report. By the end of 2032, the market is expected to reach US$ 14.8 Bn. The demand for tethered pumps is projected to garner an absolute dollar opportunity of US$ 6.7 Bn during 2022 – 2032.

One of the reasons driving market expansion is an increase in the incidence of diabetes owing to age, obesity, and an unhealthy lifestyle. Obesity is a primary cause of diabetes, which leads to a rise in the prevalence of diabetes-related ocular illnesses. In 2017, the worldwide incidence of diabetes was estimated to be about 22.9 million, the prevalence was reported to be around 476 million, 1.37 million fatalities were recorded owing to diabetes, and 1.37 million disability-adjusted life-years (DALYs) were reported to be related to diabetes. According to the WHO, over 1.9 billion individuals were overweight in 2017, with around 650 million people classed as obese.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15803

Obesity and being overweight are risk factors that are increasing the occurrence of type II diabetes. As a result, risk factors such as smoking, being overweight, being obese, and having high cholesterol are likely to increase the prevalence of type II diabetes.

Competitive Landscape

Over the projected period, rising emphasis on innovations and investments among public and private entities is expected to strengthen competition in the market. In addition, product commercialization and partnership tactics are expected to be profitable in the upcoming years.

The key vendors in the global Insulin Pump market are Cellenovo, Sooil Development, Valeritas, Inc, JingasuDelfu Co., Ltd., Medtronic plc, Hoffmann-La Roche Ltd, Tandem Diabetic Care, Inc., Insulet Corporation, and Ypsomed.

Some of the recent developments in Insulin Pump market are:

• In June 2019, Medtronic announced a partnership with Tidepool to develop an interoperable automated insulin pump system. The Medtronic MiniMed pump will serve as one of Tidepool Loop’s accessories, designed to communicate with Apple devices.
• In September 2020, Insulet Corporation, stated that its Omnipod DASH Insulin Management System would be widely available in Israel, Switzerland, Austria, Germany, Belgium, and France in the coming weeks. Denmark, Norway, Finland, and Sweden have already exposure to this product.
• In June 2020, Tandem Diabetes Care and Abbott announced a collaboration to develop and commercialize integrated diabetes care solutions. These products will combine Abbott’s continuous glucose monitoring technology with Tandem’s ground-breaking insulin delivery devices to better diabetic blood sugar control.
• In September 2020, Medtronic announced that their MiniMedTM 770G hybrid closed loop system has received FDA clearance in the United States. This unique insulin administration system, which is equipped with the company’s SmartGuard technology, and can be connected to a smartphone and can be modified for youngsters as young as two years old.

Request for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-15803

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Insulin Pump market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Type (Patch Pumps, Tethered Pumps), Product Type (Tandem (T: slim X2, G4, T: flex Delivery System), Accu-Chek (Combo, Insight, and Solo), MiniMed (630G, 670G, and VEO), Omnipod, My Life Omnipod and Other Product Types), Accessories (Insulin reservoir or cartridges, Insulin set insertion devices and Battery) Across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Market Segments Covered in Insulin Pump Industry Analysis

By Type:

• Patch Pumps
• Tethered Pumps

By Product Type:

• Tandem
• Accu-Chek
• MiniMed
• Omnipod
• My Life Omnipod
• Other Product Types

By Accessories:

• Insulin reservoir or cartridges
• Insulin set insertion devices
• Battery

Speak to our Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-15803 

By End-User:

• Homecare
• Hospitals & clinics
• Laboratories

By Region:

• North America
• Latin America
• Europe
• APAC
• MEA

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs

The Outpatient Clinics Market is anticipated to reach US$ 39.0 billion by the end of 2022 and continue to grow at a CAGR of 4.2% from 2022 to 2032. By the end of 2032, the market is anticipated to have a US$58.9 billion valuation. The market is being led by primary care clinics, which in 2021 had a share of roughly 32.6%.

Growing advancements in medical technology has led to development of treatment techniques and medications that do not require the patients to stay for long hours at the clinics or hospitals. However, imposition of strict regulations will continue to hinder the global market growth of outpatient disorders over the forecast period. Future Market Insights states that the global market of outpatient clinics is projected to reflect a CAGR of 4.3%, representing more than US$ 39,000 Mn by 2022-end.

Request for the Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-5697

Factors Fueling Global Market Growth

Growth of the global outpatient clinics market is mainly bound to various macro-economic and micro-economic factors. Prevalence of chronic diseases such as asthma, diabetes, depression and congestive heart failures lead to complex and severe health problems. With the escalating cost of treatment process in various healthcare organizations, patients prefer visiting the outpatient clinics for accessing treatment. Growing concerns regarding the increasing prevalence of cardiovascular diseases such as elevated blood pressure levels, hypertension, coronary heart diseases and cerebrovascular diseases has further led to surge in demand for the outpatient clinics globally.

Demand for quick and effective treatment of cardiovascular diseases will continue to contribute towards the global market growth of outpatient disorders. According to a recently published report by CDC, nearly 610,000 people die of heart attack in the U.S. each year, which is 1 in every 4 deaths. As cardiovascular diseases continue to remain a leading cause of mortality globally, demand for effective and quick treatment process will continue to remain high. These factors are projected to impact the global market growth of outpatient clinics throughout the forecast period.

Request Customization@ https://www.futuremarketinsights.com/customization-available/rep-gb-5697

Collaborations among the private insurance companies and outpatient clinics will continue to remain a major trend in the global market. Through collaborations the private insurance companies offer payment and services in outpatient clinics. Imposition of regulations such as Health Care and Educational Reconciliation Act and Patient Care Affordable Act provides the U.S. citizens with the public health insurance coverage and offers access to private health insurance services. Moreover, increasing employee benefits such as Employees’ health insurance by the employers is projected to contribute towards the global market growth of outpatient clinics over the forecast period.

However, the global market of outpatient clinics will continue to witness inhibiting growth attributed to various factors. Imposition of strict regulations and limited number of doctors for the treatment of various diseases will remain a key factor inhibiting demand for services offered by outpatient clinics. As the patients are not monitored for a long period of time, risk of addiction to alcohol and drugs is projected to remain high. Moreover, lack of access to counselors in comparison to the residential and inpatient facility is further projected to impede the global market growth of outpatient clinics.

Ask An Analyst@ https://www.futuremarketinsights.com/ask-the-analyst/rep-gb-5697

Sales to Remain High Through Cardiology Specialty Areas

Prevalence of chronic and cardiovascular disorders is projected to fuel demand for the multi-specialty centers globally. In terms of revenue, the multi-specialty center type segment is projected to witness significant growth, representing more than US$ 8,400 Mn by 2022-end. Moreover, the multi-specialty center type segment is projected to reflect the fastest growth in the global market of outpatient clinics throughout the forecast period.

On the basis of specialty type, the dermatology segment is projected to reflect a significant CAGR through 2022. However, the cardiology specialty areas segment is projected to represent a robust revenue growth, recording more than US$ 3,000 Mn over the forecast period.

Market Players                

Major players in the global market of outpatient clinics are Kaiser Permanente Inc., M D Anderson Cancer Center, Mayo Clinic, Memorial Sloan Kettering, University of Maryland Medical Center, DaVita Inc., Cleveland Clinic, Fresenius Medical Care and Johns Hopkins Medicine.

Key Segments Covered in Outpatient Clinics Market Report

By Clinic:
Primary Care Clinics
Community Health Clinics
Specialized Outpatient Centers
Emergency Departments
Outpatient Pharmacies

By Specialty Area:

Cardiology
Orthopedics
Gastroenterology
Dental
Ophthalmology
Urology
Neurology
Dermatology

Have a Look at Related Research Reports:

Varicella Vaccines Market

Liposuction Market

Foot And Ankle Devices Market

Mortuary Equipment Market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse All Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

Global Intravenous Iron Drugs Market was valued at US$ 2.6 Bn in 2021 and is expected to reach US$ 6.3 Bn by 2032, finds Fact.MR in a recent market survey. As per the findings of the report, Intravenous Iron Drugs revenue through Ferric Carboxymaltose will garner significant demand in the market as the bulk of revenue will be generated through them.

The American Heart Association predicts that by 2035, more than 130 million adults in the United States will have cardiovascular disease. In addition, the Centers for Disease Control and Prevention reports that 0.6 million Americans die each year from heart disease. This information leads directly to the number of hospital admissions.

The Ferric Carboxymaltose (FCM) segment led the market for intravenous iron medicines in 2021, with nearly 50% revenue share due to its expanding use, improved performance, and lower cost. It is a parenteral iron medication devoid of dextran which is suggested for the quick and high-dose replacement of depleted iron reserves. This medicine is a stable compound with the benefit of not containing any extraneous ingredients and having a very low immunogenic potential; hence, it poses a very low risk of anaphylactic responses. FCM has a higher effectiveness in terms of boosting hemoglobin levels and has fewer side effects. The tremendous rise may also be attributed to the FDA approval of Injectates in North America as well as its approval outside of North America.

Request Sample @ https://www.futuremarketinsights.com/reports/sample/rep-gb-15851

The region’s expanding senior population is a primary driver of industry development. According to US Census Bureau forecasts, the number of Americans aged 65 and older would rise from 52 million in 2018 to roughly 95 million by 2060. Furthermore, the overall percentage of people aged 65 and older is projected to increase from 16% to 23%.

It may be linked to the presence of a higher incidence of cancer, intestinal illnesses, and renal disease in the specific area. These conditions also are reinforcing its dominance. It has also contributed to the growth of women’s health awareness and the awareness about celiac disease.

Competitive Landscape

Some of the key players in the global Intravenous Iron Drugs market include Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; Shield Therapeutics Plc; AbbVie Inc., Vifor Pharma Management Ltd.; AMAG Pharmaceuticals; Daiichi Sankyo Company, Ltd.; Sanofi S.A.; Pharmacosmos A/S; and Shield Therapeutics Plc among others.

Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-15851

Some of the recent developments in the Intravenous Iron Drugs Market are:

• In April 2018, AMAG Pharmaceuticals got FDA clearance for a supplementary new drug application for ferumoxytol injection to cover all eligible people with iron-deficiency anaemia (IDA) who cannot tolerate or do not respond to oral iron.
• In May 2019, Rockwell Medical, Inc. filed a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for the Intravenous (I.V.) version of Triferic.
• In September 2020, Daiichi Sankyo announced the formation of its wholly-owned subsidiary Daiichi Sankyo Vietnam Company Limited. This program was launched in order to strengthen the company’s Asian business platform.

More Insights Available

Future Market Insights, in its new offering, presents an unbiased analysis of the Intravenous Iron Drugs Market, presenting historical market data (2017-2021) and forecast statistics for the period of 2022-2032.

The study reveals essential insights on the basis of Product Type (Iron Dextran, Iron Sucrose, Ferric Carboxymaltose, Other Product Types), by Indication (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Other Applications), across five regions (North America, Latin America, Europe, Asia Pacific and Middle East & Africa).

Use promo code ->> FMITODAY to get flat 30% discount

Market Segments Covered in Intravenous Iron Drugs Industry Analysis

By Product Type:

• Iron Dextran
• Iron Sucrose
• Ferric Carboxymaltose
• Other Product Types

By Indication:

• Chronic Kidney Disease
• Inflammatory Bowel Disease
• Cancer
• Other Applications

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:
Future Market Insights,
Unit No: 1602-006,
Jumeirah Bay 2,
Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers,
Dubai,
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs

Over the forecast period (2022-2032), it is expected that worldwide sales of Over-The-Counter (OTC) Veterinary Drugs Market medications would increase at a CAGR of 8.1% and reach US$ 18.14 Bn by the end of 2032. In 2021, online pharmacies held a market share of more than 38%.

According to Future Market Insights, the global over-the-counter (OTC) veterinary drugs market sales were worth US$ 8.32 Bn in 2022 and the market is poised to expand at a CAGR of 8.10% over the forecast period (2022-2032).

The high cost of pet healthcare and medications has led to the growth of the pet insurance sector. The North American Pet Insurance Association’s report stated that around 3.45 million pets were covered under pet insurance by May 2021, with an average growth rate of 23.4%.

Request a Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-9190

Online pharmacies have gained an impetus in the last two years mainly due to the worldwide lockdown leading to the need for doorstep delivery of medicines. For instance, in a report published by the Federation of Indian Chambers of Commerce & Industry, approximately 9 million households used e-Pharmacy services.

They have also estimated an exponential increase in the ePharmacy service usage by 2025, wherein around 70 million households would be using ePharmacy. This paradigm shift in consumer buying behaviour will create lucrative opportunities for growth in the global market.

Further, key players are focusing on product launches, strategic partnerships and acquisitions to expand their consumer base and provide better services across the world.

Get Customization on this Report – https://www.futuremarketinsights.com/customization-available/rep-gb-9190

Key Takeaways:

• The anti-parasitic drugs, within the drug class segment, are expected to account for a 12.8% market share in the global over-the-counter (OTC) veterinary drugs market, exhibiting growth at a CAGR of 8.10% over the forecast period (2022-2032).
• By product form, the oral drugs are set to capture more than 75% market share of the global Over-The-Counter (OTC) veterinary drugs market at a CAGR of 7.9% between 2022 and 2032.
• The online pharmacies, among sales channels, are expected to account for 37.8% market share in the global Over-The-Counter (OTC) veterinary drugs market in 2022.
• North America will dominate the global over-the-counter (OTC) veterinary drugs market with a market share of 34.7% by the end of 2022.

Leading Companies Profiled:

• Zoetis
• Boehringer Ingelheim
• Virbac S.A.
• Hester Biosciences Ltd.
• Merck Animal Health
• Elanco Animal Health
• Ceva Santé Animale
• Vetoquinol S.A.
• Phibro Animal Health Corporation
• Dechra Pharmaceuticals PLC
• Kyoritsu Seiyaku Corporation

“Rising awareness of antibiotic resistance, increased pet adoption rate and growing pet-related diseases are driving the demand for global OTC veterinary drugs over the forecast period,” says an analyst of Future Market Insights.

Market Competition:

Product launches, strategic collaborations, and acquisitions are some of the key strategies adopted by the OTC veterinary drug manufacturers to expand their product portfolio.

• In April 2021, on World Veterinary Day 2021, Hester Biosciences announced the launch of their new product line of herbal products for livestock and poultry.
• In September 2021, Virbac and Jectas Innovators announced the formation of their collaborative agreement to expand their animal health vaccine segment.
• In August 2020, Merck Animal Health announced the acquisition of IdentiGEN, a leader in DNA-based animal traceability solutions for Livestock and Aquaculture.
• In September 2020, Boehringer Ingelheim acquired an equity stake in New Ruipeng Group (NRP Group), which operates digital and clinical pet services across China.

Ask an Analyst at https://www.futuremarketinsights.com/ask-question/rep-gb-9190

Key Market Segments

By Drug Class:

• NSAIDs
• Antihistamines
• Decongestants & Bronchodilators
• Antibacterial
• H2 Receptor Antagonists
• Nutrients & Supplements
• Glucocorticoids
• Lubricant eye drops & artificial tears
• Anti-parasitic
• Antidiarrheal agents
• Others

By Product Form:

• Oral
• Injectable
• Topical
• Others

By Sales Channel:

• Veterinary Hospitals
• Veterinary Clinics
• Retail Pharmacies
• Hypermarkets & Supermarkets
• Online Pharmacies
• Veterinary Shops

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Want more insights?

Future Market Insights brings a comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2032. The global extraction kits market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

The study provides compelling insights on the Over-The-Counter (OTC) veterinary drugs market based on drug class (Non-steroidal Anti-inflammatory Drug (NSAID), antihistamines, decongestant and bronchodilator, antibacterial, H2 receptor antagonists, nutrients and supplements, glucocorticoids, lubricant eye drops and artificial tears, anti-parasitic, antidiarrheal agents and others), by product form (oral, injectable, topical and others), and sales channel (veterinary hospitals, veterinary clinics, retail pharmacies, hypermarkets and supermarkets, online pharmacies and veterinary shops) across seven major regions.

Top Related Reports Healthcare Market Insights:

Single-use Bioprocessing Probes and Sensors Market

Medical Chairs Market

Veterinary Services Market

Acid Citrate Dextrose Tubes Market

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.

Christiana Corporate, 200 Continental Drive,

Suite 401, Newark, Delaware – 19713, USA

T: +1-845-579-5705

For Sales Enquiries: sales@futuremarketinsights.com

Browse All Reports: https://www.futuremarketinsights.com/reports

LinkedIn| Twitter| Blogs

[297 Pages Report] The global IoT in healthcare market is projected to reach US$ 181.4 Billion in 2022, anticipated to grow at a CAGR of 18.0%, reaching US$ 952.3 Billion by 2032. The market is slated to document a Y-o-Y growth rate of 20.7% from 2021-2022, increasing from the previously registered value of US$ 150.3 Billion.

By enabling real-time patient data access and remote patient monitoring, the Internet of Things (IoT) has the potential to disrupt traditional paper-based healthcare therapy. With the emergence of this digital healthcare technology, the impending need for enhanced diagnostics and targeted therapeutic options was met.

Furthermore, it not only enables physicians to remotely monitor patients, but it also functions as a fitness and wellness tracker for athletes and a dose reminder for patients. The successful implementation of IoT in remote monitoring of diabetic and asthma patients, along with the growing usage of fitness and wellness devices, has resulted in a considerable demand for the IoT healthcare business.

Download FREE Sample Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14639

Key Takeaways from the Market Study

•IoT in healthcare experienced a growth rate worth 18.8% between 2015 and 2021

•Portable diagnostic devices in the IoT in Healthcare segment to expand at a CAGR of 10.1% during the forecast period

•In the U.S., the market is predicted to reach US$ 208.1 Billion while growing at a CAGR of 18.9% during the forecast period

•China’s market is expected to reach a market value of US$ 92.8 Billion with a CAGR of 19.5% during the forecast period

“Big data analytics is an area of IoT that is quickly expanding. The most recent breakthroughs in machine learning, logical procedures, computational intelligence, and data mining are required for big data analytics”, says an FMI analyst.

Competitive Landscape

Ask for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-14639

Key players that have been profiled in the report are Apple Inc., Cisco Systems Inc., GE Healthcare Ltd., Google (Alphabet), International Business Machines
Corporation, Medtronic PLC, Microsoft Corporation, Proteus Digital Health, Koninklijke Philips N.V., QUALCOMM Incorporated, and Abbot Laboratories are among companies that offer products and technologies that will allow customers to take advantage of new technologies.

•In April 2019, Royal Philips and Spencer Health Solutions expanded their relationship to provide chronically sick patients in selected European Union (EU) nations with in-home medication adherence and the Philips telehealth platform.

•Medtronic worked with IBM Watson in January 2019 to provide IQcast, a new feature of its current product Sugar.IQ, for iOS mobile devices in the United States. The software would provide patients with a hypoglycemic episode to monitor their low glucose level by anticipating the occurrence 1 to 4 hours in advance.

Key Segments Covered in the IoT in Healthcare Industry Report

IoT in Healthcare by Component:

• IoT in Healthcare Hardware
  • Portable Diagnostic Devices
  • Non-Portable Diagnostic Devices
• IoT in Healthcare Software
• IoT in Healthcare Services

IoT in Healthcare by Application:

• IoT in Healthcare for Telemedicine
• IoT in Healthcare for Medication Management
• IoT in Healthcare for Clinical Operations
• IoT in Healthcare for Patient Monitoring
• IoT in Healthcare for Connected Imaging
• Other IoT in Healthcare Applications

IoT in Healthcare by Technology:

• Bluetooth-based IoT in Healthcare
• Wi-Fi-based IoT in Healthcare
• NFC-based IoT in Healthcare
• Zigbee-based IoT in Healthcare
• RFID-based IoT in Healthcare
• Other IoT in Healthcare Technologies (Cellular, Satellite, Zwave, EnOcean)

IoT in Healthcare by End User:

• IoT in Healthcare across Hospitals
• IoT in Healthcare across Pharmaceuticals
• IoT in Healthcare across Clinics & Laboratories

Explore FMI’s Extensive ongoing Coverage on Healthcare Domain

Complex Regional Pain Syndrome (CRPS) Market Demand : The global market for complex regional pain syndrome (CRPS) is estimated to be worth US$ 101.9 Million in 2022, rising to US$ 126.7 Million by 2032.

IoT in Healthcare Market Size : The global IoT in healthcare market is projected to reach US$ 181.4 Billion in 2022, anticipated to grow at a CAGR of 18.0%, reaching US$ 952.3 Billion by 2032.

Robotic Wheelchair Market Share : The global demand for the robotic wheelchair market is set to witness growth at 11.5% CAGR from 2022 to 2032, surpassing US$ 127.1 Mn in 2022.

The global Oligonucleotide API Market is expected to reach US$ 2.46 billion in 2022, with a CAGR of 10.2% through 2030, according to FMI, an ESOMAR-certified market research firm.

According to FMI’s analysis, as of now, 100+ oligonucleotide APIs are in the clinical trials’ phase, and regulatory approval is on the cards. Post-approval, the demand for production capacity will witness an exponentiation, thereby driving the oligonucleotide API market through 2030.

Oligonucleotides are being looked upon as the subsequent large group of therapeutics following biologics and molecules. This could be attributed to the assurance on their part to develop drugs at lower costs.

Request a Sample of this Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-11933

Apart from immune therapy, microbial and cardiovascular infections, and cancer, oligonucleotide APIs are being tried out to treat neurological disorders like Alzheimer’s as well. However, factors like regulatory complexities and timely delivery of oligonucleotides (amidst Covid-19) are acting as restraints.

Key Takeaways from Oligonucleotide API Marker Study

• Antisense Oligonucleotides APIs are anticipated to reach US$ 4 Bn by 2030.
• North America and Europe collectively accounted for more than 47% of revenue share in 2019 while Asia Pacific is expected to grow at the fastest rate in the forecast period.
• Increase in use of antisense oligonucleotide APIs (especially post approval from US FDA in 2016) to boost the market in the forecast period

Request Discount @ https://www.futuremarketinsights.com/request-discount/rep-gb-11933

“Inorganic mode of growth coupled with broad therapeutic applications in gene therapy is expected to bolster the oligonucleotide API market” says the FMI analyst.

New Product Launches: Key Indicators to Oligonucleotide APIs Market

FMI has analyzed players such as Akcea Therapeutics, Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., and Dynavax Technologies in this report. According to the analysis, these players are consolidating their positions through new product launches.

For instance –

• In Mar 2020, Dynavax entered into collaboration with Clover Biopharmaceuticals for developing a vaccine candidate to combat Covid-19. Clover is into advanced evaluation of its Covid-19 S-Trimer, protein-based coronavirus vaccine candidate and Dynavax has its technical expertise along with proprietary toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018 for executing this.
• Alnylam Pharmaceuticals, Inc., in 2018, launched Givlaari and Onpattro at the commercial level.

Ask for Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-11933

Gene Therapy and Oligonucleotide APIs

Synthetic oligonucleotides are being used in gene therapy for inactivating genes that help in propagating the disease. Antisense oligonucleotide APIs are used for disrupting the faulty gene’s transcription.

Also, siRNA could be used for signaling the cell to disrupt faulty mRNA’s translation. Along these lines, Pharmamar, in Jan 2020, signed an agreement with Jazz Pharmaceuticals for selling the API for “lurbinectedin”, one of the late-phase treatments for SCLC (small cell lung cancer) so that the latter could commercialize it.

Key Segments of Oligonucleotide API Industry Survey: 

Oligonucleotide API Market by API:

• Antisense Oligonucleotides APIs
• Short Interfering RNA (siRNA) APIs
• Phosphorodiamidate Morpholino Oligonucleotides (PMO) APIs
• MiRNA APIs
• Aptamers APIs
• CpG Oligonucleotides APIs
• Others (ON Conjugates (NP), ShRNA, etc.)

Oligonucleotide API Market by Marketing Status:

• Marketed
• Clinical Trials (Clinical Phases)

Oligonucleotide API Market by End User:

• Contract Manufacturing Organizations (CMOs)
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Development & Manufacturing Organizations (CDMOs)

Oligonucleotide API Market by Region:

• North America Oligonucleotide API Market
• Latin America Oligonucleotide API Market
• Europe Oligonucleotide API Market
• East Asia Oligonucleotide API Market
• South Asia & Pacific Oligonucleotide API Market
• Middle East & Africa (MEA) Oligonucleotide API Market

Buy This Report: https://www.futuremarketinsights.com/checkout/11933

Key Companies Profiled:

• Jazz Pharmaceuticals, Inc.
• Sarepta Therapeutics
• Biogen
• Dynavax Technologies
• Akcea Therapeutics.
• Alnylam Pharmaceuticals, Inc.

Explore Wide-ranging Coverage of FMI’s Healthcare Landscape:

• https://gab.com/Jaydip123/posts/109518218681923556
• https://likefm.org/blog/self-testing-market-size-share-application-analysis-and-growth-by-forecast-to-2022-2030
• https://adhipatialumni.com/blogs/63007/Self-Testing-Market-Size-Share-Application-Analysis-and-Growth-by
• https://writeablog.net/jaydip-fmi/self-testing-market-size-share-application-analysis-and-growth-by-forecast-to
• https://anotepad.com/notes/daktdf2m

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 8-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs